Published in Curr Alzheimer Res on May 01, 2012
Anti-tau antibodies that block tau aggregate seeding in vitro markedly decrease pathology and improve cognition in vivo. Neuron (2013) 3.09
Alzheimer disease therapy--moving from amyloid-β to tau. Nat Rev Neurol (2013) 1.31
Prion-like properties of Tau protein: the importance of extracellular Tau as a therapeutic target. J Biol Chem (2014) 1.20
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem (2013) 1.12
Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. Acta Neuropathol Commun (2014) 1.09
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies. Pharmacol Ther (2013) 1.06
Two novel Tau antibodies targeting the 396/404 region are primarily taken up by neurons and reduce Tau protein pathology. J Biol Chem (2013) 1.00
Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy. PLoS One (2013) 1.00
Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials. Acta Neuropathol (2014) 0.99
Advances in the development of vaccines for Alzheimer's disease. Discov Med (2013) 0.97
Passive immunization with phospho-tau antibodies reduces tau pathology and functional deficits in two distinct mouse tauopathy models. PLoS One (2015) 0.97
Tau aggregation and its interplay with amyloid-β. Acta Neuropathol (2014) 0.93
First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther (2014) 0.93
Tau as a therapeutic target in neurodegenerative disease. Pharmacol Ther (2012) 0.92
Ectosomes: a new mechanism for non-exosomal secretion of tau protein. PLoS One (2014) 0.92
Immunotherapeutic Approaches Targeting Amyloid-β, α-Synuclein, and Tau for the Treatment of Neurodegenerative Disorders. Neurotherapeutics (2016) 0.90
Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem Pharmacol (2014) 0.90
Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol (2015) 0.89
A fresh perspective from immunologists and vaccine researchers: Active vaccination strategies to prevent and reverse Alzheimer's disease. Alzheimers Dement (2015) 0.89
Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy. Mol Neurodegener (2015) 0.88
Prion-like propagation of protein aggregation and related therapeutic strategies. Neurotherapeutics (2013) 0.88
Passive immunization targeting the N-terminal projection domain of tau decreases tau pathology and improves cognition in a transgenic mouse model of Alzheimer disease and tauopathies. J Neural Transm (Vienna) (2014) 0.87
Microglial internalization and degradation of pathological tau is enhanced by an anti-tau monoclonal antibody. Sci Rep (2015) 0.86
Alzheimer's disease and immunotherapy. Aging Dis (2013) 0.86
Tau-based therapeutic approaches for Alzheimer's disease - a mini-review. Gerontology (2014) 0.85
Passive immunotherapy of tauopathy targeting pSer413-tau: a pilot study in mice. Ann Clin Transl Neurol (2015) 0.84
Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis (2014) 0.82
The role of tau in neurodegenerative diseases and its potential as a therapeutic target. Scientifica (Cairo) (2012) 0.82
Antibody-derived in vivo imaging of tau pathology. J Neurosci (2014) 0.82
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer's disease. Alzheimers Res Ther (2014) 0.82
Tau immunotherapy and imaging. Neurodegener Dis (2013) 0.82
A2A adenosine receptor deletion is protective in a mouse model of Tauopathy. Mol Psychiatry (2014) 0.81
Tau Protein Hyperphosphorylation and Aggregation in Alzheimer's Disease and Other Tauopathies, and Possible Neuroprotective Strategies. Biomolecules (2016) 0.81
Epitope analysis following active immunization with tau proteins reveals immunogens implicated in tau pathogenesis. J Neuroinflammation (2014) 0.80
Passive Immunization in JNPL3 Transgenic Mice Using an Array of Phospho-Tau Specific Antibodies. PLoS One (2015) 0.80
Identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and Alzheimer's diseases. PLoS One (2013) 0.79
Tau Immunotherapy. Neurodegener Dis (2015) 0.78
Tau-Directed Immunotherapy: A Promising Strategy for Treating Alzheimer's Disease and Other Tauopathies. J Neuroimmune Pharmacol (2015) 0.78
Anti-amyloid beta to tau - based immunization: Developments in immunotherapy for Alzheimer disease. Immunotargets Ther (2013) 0.78
Stabilization of Microtubule-Unbound Tau via Tau Phosphorylation at Ser262/356 by Par-1/MARK Contributes to Augmentation of AD-Related Phosphorylation and Aβ42-Induced Tau Toxicity. PLoS Genet (2016) 0.78
Hippocampal T cell infiltration promotes neuroinflammation and cognitive decline in a mouse model of tauopathy. Brain (2016) 0.77
The structure of human tau-tubulin kinase 1 both in the apo form and in complex with an inhibitor. Acta Crystallogr F Struct Biol Commun (2014) 0.77
Internalization of tau antibody and pathological tau protein detected with a flow cytometry multiplexing approach. Alzheimers Dement (2016) 0.76
Tau passive immunization inhibits not only tau but also Aβ pathology. Alzheimers Res Ther (2017) 0.76
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target? Immunotargets Ther (2013) 0.75
Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation. Vaccines (Basel) (2014) 0.75
MultiTEP platform-based DNA epitope vaccine targeting N-terminus of tau induces strong immune responses and reduces tau pathology in THY-Tau22 mice. Vaccine (2017) 0.75
Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency. Mol Neurodegener (2017) 0.75
Tracking progressive pathological and functional decline in the rTg4510 mouse model of tauopathy. Alzheimers Res Ther (2017) 0.75
Generation and characterization of new monoclonal antibodies targeting the PHF1 and AT8 epitopes on human tau. Acta Neuropathol Commun (2017) 0.75
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol (2009) 7.50
Formation of neurofibrillary tangles in P301l tau transgenic mice induced by Abeta 42 fibrils. Science (2001) 6.17
Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem (2009) 5.76
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev (2000) 5.40
Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol (2002) 3.48
Age-dependent neurofibrillary tangle formation, neuron loss, and memory impairment in a mouse model of human tauopathy (P301L). J Neurosci (2005) 3.20
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci (2007) 3.10
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci (2002) 2.80
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45
Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer's disease paired helical filament tau. Neuron (1994) 2.13
Active and passive immunotherapy for neurodegenerative disorders. Annu Rev Neurosci (2008) 2.01
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem (2011) 1.91
Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin. J Neurosci (2009) 1.88
Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci (2009) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am J Pathol (2006) 1.68
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice. Exp Neurol (2010) 1.61
Assembly of tau in transgenic animals expressing P301L tau: alteration of phosphorylation and solubility. J Neurochem (2002) 1.57
Getting into the brain: approaches to enhance brain drug delivery. CNS Drugs (2009) 1.47
Extracellular tau is toxic to neuronal cells. FEBS Lett (2006) 1.47
A conformation- and phosphorylation-dependent antibody recognizing the paired helical filaments of Alzheimer's disease. J Neurochem (1997) 1.47
Pseudophosphorylation of tau at serine 422 inhibits caspase cleavage: in vitro evidence and implications for tangle formation in vivo. J Neurochem (2006) 1.39
Tauopathy-like abnormalities and neurologic deficits in mice immunized with neuronal tau protein. Arch Neurol (2006) 1.38
Early axonopathy preceding neurofibrillary tangles in mutant tau transgenic mice. Am J Pathol (2007) 1.26
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis (2008) 1.22
Divergent phosphorylation pattern of tau in P301L tau transgenic mice. Eur J Neurosci (2008) 1.21
Characterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett (1996) 1.16
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
C-terminal truncation modulates both nucleation and extension phases of tau fibrillization. FEBS Lett (2005) 1.09
Role of phosphorylation in the conformation of tau peptides implicated in Alzheimer's disease. Biochemistry (2000) 1.06
Starvation induces tau hyperphosphorylation in mouse brain: implications for Alzheimer's disease. FEBS Lett (1999) 1.06
Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Neurobiol Dis (2009) 1.02
Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathol (2003) 1.00
Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis (2011) 1.00
Mechanisms of A beta plaque clearance following passive A beta immunization. Neurodegener Dis (2005) 0.96
Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem (2010) 0.96
Phosphorylated serine422 on tau proteins is a pathological epitope found in several diseases with neurofibrillary degeneration. Acta Neuropathol (1999) 0.92
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res (2011) 0.91
Tau as a therapeutic target for Alzheimer's disease. Curr Alzheimer Res (2011) 0.89
Phosphorylation of microtubule-associated protein tau by stress-activated protein kinases in intact cells. FEBS Lett (2002) 0.88
Intra-peritoneal injection of polyclonal anti-interferon alpha antibodies cross the blood brain barrier and neutralize interferon alpha. Neurochem Res (2008) 0.86
Active versus passive immunization against hepatitis A in the Israel defence forces: a cost-benefit analysis. Vaccine (2000) 0.79
Induction of a specific tau Alzheimer epitope in SY-5Y neuroblastoma cells. Neuroreport (1996) 0.78
Ubiquitin-negative mini-pick-like bodies in the dentate gyrus in p301l tauopathy. J Alzheimers Dis (2003) 0.77
Tau phosphorylation and sevoflurane anesthesia: an association to postoperative cognitive impairment. Anesthesiology (2012) 2.87
Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain (2006) 2.71
Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol (2004) 2.15
Electrosurgery and implantable electronic devices: review and implications for office-based procedures. Dermatol Surg (2011) 2.07
Misregulated alternative splicing of BIN1 is associated with T tubule alterations and muscle weakness in myotonic dystrophy. Nat Med (2011) 1.87
Genetic ablation of Dicer in adult forebrain neurons results in abnormal tau hyperphosphorylation and neurodegeneration. Hum Mol Genet (2010) 1.83
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem (2005) 1.68
Symptoms of B12 deficiency can occur in women of child bearing age supplemented with folate. Neurology (2002) 1.63
Non-steroidal anti-inflammatory treatment in cancer cachexia: a systematic literature review. Acta Oncol (2012) 1.49
Nuclear tau, a key player in neuronal DNA protection. J Biol Chem (2010) 1.47
Premature ovarian aging in mice deficient for Gpr3. Proc Natl Acad Sci U S A (2005) 1.41
Alkalizing drugs induce accumulation of amyloid precursor protein by-products in luminal vesicles of multivesicular bodies. J Biol Chem (2007) 1.35
Involvement of beta-site APP cleaving enzyme 1 (BACE1) in amyloid precursor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc Natl Acad Sci U S A (2007) 1.30
Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics (2008) 1.21
Targeting specific regions of the Notch3 ligand-binding domain induces apoptosis and inhibits tumor growth in lung cancer. Cancer Res (2010) 1.13
MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum Mol Genet (2011) 1.11
Effects of remifentanil on N-methyl-D-aspartate receptor: an electrophysiologic study in rat spinal cord. Anesthesiology (2005) 1.08
From tau phosphorylation to tau aggregation: what about neuronal death? Biochem Soc Trans (2010) 1.08
6-Hydroxydopamine activates the mitochondrial apoptosis pathway through p38 MAPK-mediated, p53-independent activation of Bax and PUMA. J Neurochem (2007) 1.07
The influence of comorbid depression on quality of life for people with epilepsy. Epilepsy Behav (2003) 1.07
Neurotoxicity and memory deficits induced by soluble low-molecular-weight amyloid-β1-42 oligomers are revealed in vivo by using a novel animal model. J Neurosci (2012) 1.06
Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease. Front Physiol (2012) 1.05
Invasive palliative interventions: when are they worth it and when are they not? Cancer J (2010) 1.04
A genetic variation in the ADORA2A gene modifies age at onset in Huntington's disease. Neurobiol Dis (2009) 1.04
Altered neuronal excitability in cerebellar granule cells of mice lacking calretinin. J Neurosci (2003) 1.04
The peptidylprolyl cis/trans-isomerase Pin1 modulates stress-induced dephosphorylation of Tau in neurons. Implication in a pathological mechanism related to Alzheimer disease. J Biol Chem (2006) 1.03
Phosphorylation of amyloid precursor carboxy-terminal fragments enhances their processing by a gamma-secretase-dependent mechanism. Neurobiol Dis (2005) 1.03
Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol (2002) 1.03
Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiol Dis (2007) 1.02
Pin1 allows for differential Tau dephosphorylation in neuronal cells. Mol Cell Neurosci (2006) 1.02
ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J Neurosci Res (2006) 1.01
Brain-specific change in alternative splicing of Tau exon 6 in myotonic dystrophy type 1. Biochim Biophys Acta (2005) 1.01
The impact of comorbid depression on health resource utilization in a community sample of people with epilepsy. Epilepsy Behav (2004) 1.00
Beneficial effects of exercise in a transgenic mouse model of Alzheimer's disease-like Tau pathology. Neurobiol Dis (2011) 1.00
The influence of comorbid depression on seizure severity. Epilepsia (2003) 0.99
Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis (2005) 0.98
Neurofilament ELISA validation. J Immunol Methods (2009) 0.96
Mitochondria and calcium flux as targets of neuroprotection caused by minocycline in cerebellar granule cells. Biochem Pharmacol (2009) 0.96
Hippocampal tauopathy in tau transgenic mice coincides with impaired hippocampus-dependent learning and memory, and attenuated late-phase long-term depression of synaptic transmission. Neurobiol Learn Mem (2010) 0.96
Association between caffeine intake and age at onset in Huntington's disease. Neurobiol Dis (2013) 0.94
Analysis of exonic regions involved in nuclear localization, splicing activity, and dimerization of Muscleblind-like-1 isoforms. J Biol Chem (2011) 0.94
Functions, dysfunctions and possible therapeutic relevance of adenosine A2A receptors in Huntington's disease. Prog Neurobiol (2007) 0.94
Nutrition impact symptoms in advanced cancer patients: frequency and specific interventions, a case-control study. J Cachexia Sarcopenia Muscle (2013) 0.94
Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. Eur J Neurosci (2007) 0.93
Detrimental effects of diet-induced obesity on τ pathology are independent of insulin resistance in τ transgenic mice. Diabetes (2012) 0.93
D-β-hydroxybutyrate is protective in mouse models of Huntington's disease. PLoS One (2011) 0.92
Expression of human FE65 in amyloid precursor protein transgenic mice is associated with a reduction in beta-amyloid load. J Neurochem (2005) 0.91
Tau as a biomarker of neurodegenerative diseases. Biomark Med (2008) 0.91
Stem cell factor and mesenchymal and neural stem cell transplantation in a rat model of Huntington's disease. Mol Cell Neurosci (2007) 0.91
Abnormal Tau phosphorylation of the Alzheimer-type also occurs during mitosis. J Neurochem (2002) 0.91
Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage (2007) 0.91
Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain. Neuropharmacology (2005) 0.89
Phosphorylated serine 199 of microtubule-associated protein tau is a neuronal epitope abundantly expressed in youth and an early marker of tau pathology. Acta Neuropathol (2002) 0.89
Epstein-Barr virus protein EB2 contains an N-terminal transferable nuclear export signal that promotes nucleocytoplasmic export by directly binding TAP/NXF1. J Virol (2009) 0.89
MicroRNAs and the Regulation of Tau Metabolism. Int J Alzheimers Dis (2012) 0.89
Weight loss, appetite loss and food intake in cancer patients with cancer cachexia: three peas in a pod? - analysis from a multicenter cross sectional study. Acta Oncol (2013) 0.88
A new locus for spinocerebellar ataxia (SCA21) maps to chromosome 7p21.3-p15.1. Ann Neurol (2002) 0.88
Worsening of Huntington disease phenotype in CB1 receptor knockout mice. Neurobiol Dis (2011) 0.88
Argyrophilic grain disease and Alzheimer's disease are distinguished by their different distribution of tau protein isoforms. Acta Neuropathol (2002) 0.88
Guadeloupean parkinsonism: a cluster of progressive supranuclear palsy-like tauopathy. Brain (2002) 0.87
NMDA receptor dysfunction contributes to impaired brain-derived neurotrophic factor-induced facilitation of hippocampal synaptic transmission in a Tau transgenic model. Aging Cell (2012) 0.87
Association of plasma Aß peptides with blood pressure in the elderly. PLoS One (2011) 0.86
Ghrelin-induced hypothermia: a physiological basis but no clinical risk. Physiol Behav (2011) 0.86
Two-dimensional electrophoresis of tau mutants reveals specific phosphorylation pattern likely linked to early tau conformational changes. PLoS One (2009) 0.86
Effects of the adenosine A2A receptor antagonist SCH 58621 on cyclooxygenase-2 expression, glial activation, and brain-derived neurotrophic factor availability in a rat model of striatal neurodegeneration. J Neuropathol Exp Neurol (2007) 0.86
From epidemiology to pathophysiology: what about caffeine in Alzheimer's disease? Biochem Soc Trans (2014) 0.85
Eslicarbazepine acetate as adjunctive therapy in patients with uncontrolled partial-onset seizures: Results of a phase III, double-blind, randomized, placebo-controlled trial. Epilepsia (2014) 0.85
Protein kinase CK2 phosphorylation of EB2 regulates its function in the production of Epstein-Barr virus infectious viral particles. J Virol (2007) 0.85
Clinical, neuropathological, and biochemical characterization of the novel tau mutation P332S. J Alzheimers Dis (2012) 0.85
MUC1-C nuclear localization drives invasiveness of renal cancer cells through a sheddase/gamma secretase dependent pathway. Oncotarget (2014) 0.85
Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains. Brain Res (2010) 0.84
Patient-focused endpoints in advanced cancer: criterion-based validation of accelerometer-based activity monitoring. Clin Nutr (2011) 0.84
Myotonic dystrophy CTG expansion affects synaptic vesicle proteins, neurotransmission and mouse behaviour. Brain (2013) 0.84
A non-DM1, non-DM2 multisystem myotonic disorder with frontotemporal dementia: phenotype and suggestive mapping of the DM3 locus to chromosome 15q21-24. Brain (2004) 0.84
Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer's disease. Neurosci Lett (2004) 0.84
Death of cortical and striatal neurons induced by mitochondrial defect involves differential molecular mechanisms. Neurobiol Dis (2004) 0.83
A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr Pharm Des (2008) 0.82